NCT06675643 Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
| NCT ID | NCT06675643 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Malignant Skin Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-14 |
| Primary Completion | 2027-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-10-14 with a primary completion date of 2027-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.
Eligibility Criteria
Inclusion Criteria: * Any skin cancer/melanoma patient starting dual \[ipilimumab/nivolumab (IPI/NIVO)\] immune checkpoint inhibitor (ICI) therapy Exclusion Criteria: * Does not meet inclusion criteria
Contact & Investigator
Svetomir N. Markovic, MD, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06675643 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Skin Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06675643 currently recruiting?
Yes, NCT06675643 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06675643 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06675643 clinical trial?
NCT06675643 is sponsored by Mayo Clinic. The principal investigator is Svetomir N. Markovic, MD, PhD at Mayo Clinic. The trial plans to enroll 100 participants.